Neoisoliquiritigenin inhibits tumor progression by targeting GRP78-β-catenin signaling in breast cancer.

Neoisoliquiritigenin inhibits tumor progression by targeting GRP78-β-catenin signaling in breast cancer.

Curr Cancer Drug Targets. 2017 Sep 14;:

Authors: Tang H, Peng F, Huang X, Xie X, Chen B, Shen J, Gao F, You J, Xie X, Chen J

Abstract
Although breast cancer mortality has been stable or decreasing in the world, its incidence and recurrence rates have sharply risen worldwide in recent years. Identification of novel preventative biomarkers and drugs for breast cancer has become an urgent issue worldwide. Recently, GRP78 demonstrated a critical role in mediating tumorigenesis, metastasis and angiogenesis. However, the impact of GRP78 in breast cancer and clinical characteristics remains unclear. In this study, we found that GRP78 could promote breast cancer initiation and progression, and higher expression of GRP78 indicated poorer state of breast cancer patients, suggesting that GRP78 was a significant oncogene with the potential to be a novel biomarker and target in clinical investigation. Also, according to the analysis of molecular docking, we found a derivative of Isoliquiritigenin, Neoisoliquiritigenin (NISL), showed a vital inhibitory effect on breast cancer through direct binding to GRP78 to regulate β-catenin pathway. Taken together, this study not only highlight the significance of GRP78 in breast cancer development via β-catenin signaling but also suggest NISL as a natural candidate to inhibit breast cancer by targeting GRP78.

PMID: 28914191 [PubMed - as supplied by publisher]

from Cancer via ola Kala on Inoreader http://ift.tt/2jxdbeX
via IFTTT